Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Chiara Tommasi; Rita Bellagamba; Massimo Tempestilli; Antonio D&apos;Avolio; Anna L. Gallo; Jelena Ivanovic; Emanuele Nicastri; Leopoldo P. Pucillo; Pasquale Narciso

doi:10.1186/1475-2875-10-141

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Chiara Tommasi, Rita Bellagamba, Massimo Tempestilli, Antonio D'Avolio, Anna L. Gallo, Jelena Ivanovic, Emanuele Nicastri, Leopoldo P. Pucillo, Pasquale Narciso

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.

Original language	English
Article number	141
Journal	Malaria Journal
Volume	10
DOIs	https://doi.org/10.1186/1475-2875-10-141
Publication status	Published - 2011

ASJC Scopus subject areas

Parasitology
Infectious Diseases

Access to Document

10.1186/1475-2875-10-141

Fingerprint Dive into the research topics of 'Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis'. Together they form a unique fingerprint.

Cite this

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. / Tommasi, Chiara; Bellagamba, Rita ; Tempestilli, Massimo; D'Avolio, Antonio; Gallo, Anna L.; Ivanovic, Jelena; Nicastri, Emanuele; Pucillo, Leopoldo P.; Narciso, Pasquale.

In: Malaria Journal, Vol. 10, 141, 2011.

Research output: Contribution to journal › Article › peer-review

@article{4e2ba9cb35eb44c7a12b76f8a6673a29,

title = "Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis",

abstract = "The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.",

author = "Chiara Tommasi and Rita Bellagamba and Massimo Tempestilli and Antonio D'Avolio and Gallo, {Anna L.} and Jelena Ivanovic and Emanuele Nicastri and Pucillo, {Leopoldo P.} and Pasquale Narciso",

year = "2011",

doi = "10.1186/1475-2875-10-141",

language = "English",

volume = "10",

journal = "Malaria Journal",

issn = "1475-2875",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

AU - Tommasi, Chiara

AU - Bellagamba, Rita

AU - Tempestilli, Massimo

AU - D'Avolio, Antonio

AU - Gallo, Anna L.

AU - Ivanovic, Jelena

AU - Nicastri, Emanuele

AU - Pucillo, Leopoldo P.

AU - Narciso, Pasquale

PY - 2011

Y1 - 2011

N2 - The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.

AB - The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.

UR - http://www.scopus.com/inward/record.url?scp=79956189230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956189230&partnerID=8YFLogxK

U2 - 10.1186/1475-2875-10-141

DO - 10.1186/1475-2875-10-141

M3 - Article

C2 - 21600016

AN - SCOPUS:79956189230

VL - 10

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

M1 - 141

ER -